Tabelecleucel
Lymphoproliferative Disorders
Pierre Fabre MedicamentCell therapyPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
27 Active assets in the Lymphoproliferative Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Darbepoetin Alfa Mayo Clinic | Phase 3 | BB |
Epoetin Alfa Mayo Clinic | Phase 3 | BB |
Fludarabine Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 2 | BB |
Cyclophosphamide Beijing Immunochina Medical Science & Technology Co., Ltd. | Phase 2 | BB |
Baclofen Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Tabelecleucel is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderDormant
BB
Indicative ·
66 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →